Eva Jimenez-Mora
Overview
Explore the profile of Eva Jimenez-Mora including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jimenez-Mora E, Gallego B, Diaz-Gago S, Lasa M, Baquero P, Chiloeches A
Int J Mol Sci
. 2021 Jul;
22(11).
PMID: 34204950
The dysregulation of autophagy is important in the development of many cancers, including thyroid cancer, where BRAF is a main oncogene. Here, we analyse the effect of BRAF inhibition on...
2.
Rodriguez-Alvarez F, Jimenez-Mora E, Caballero M, Gallego B, Chiloeches A, Toro M
Mol Cell Biochem
. 2015 Oct;
411(1-2):253-60.
PMID: 26472731
Somatostatin (SST) is one of the main regulators of thyroid function. It acts by binding to its receptors, which lead to the dissociation of G proteins into Gαi and Gβγ...
3.
Baquero P, Jimenez-Mora E, Santos A, Lasa M, Chiloeches A
Mol Carcinog
. 2015 Sep;
55(11):1639-1654.
PMID: 26392228
The epithelial-mesenchymal transition (EMT) is a crucial process in tumour progression, by which epithelial cells acquire a mesenchymal phenotype, increasing its motility and the ability to invade distant sites. Here,...
4.
Baquero P, Sanchez-Hernandez I, Jimenez-Mora E, Orgaz J, Jimenez B, Chiloeches A
Cancer Lett
. 2013 Feb;
335(1):232-41.
PMID: 23435375
BRAF is a main oncogene in human thyroid cancer. Here, we show that BRAF depletion by siRNA or inhibition of its activity by treatment with BRAF inhibitor PLX4720 decreases migration...